Valuation : Carlsmed, Inc.

Market Cap 426M 366M 345M 314M 588M 40.28B 590M 4.08B 1.58B 20.63B 1.6B 1.56B 65.71B P/E 2026 *
-10.5x
P/E 2027 * -10.7x
Enterprise Value 426M 366M 345M 314M 588M 40.28B 590M 4.08B 1.58B 20.63B 1.6B 1.56B 65.71B EV / Sales 2026 *
5.55x
EV / Sales 2027 * 3.94x
Free-Float
55.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.52%
1 week-4.24%
Current month-4.24%
1 month+12.88%
3 months+40.92%
6 months+30.00%
Current year+26.32%
1 week 15.38
Extreme 15.38
17.2
1 month 13.3
Extreme 13.3
17.23
Current year 8.5
Extreme 8.5
17.23
1 year 8.5
Extreme 8.5
17.23
3 years 8.5
Extreme 8.5
17.23
5 years 8.5
Extreme 8.5
17.23
10 years 8.5
Extreme 8.5
17.23
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 50 2018-06-03
Chief Executive Officer 50 2018-06-03
Director of Finance/CFO 50 2023-07-31
Director TitleAgeSince
Chairman 50 2018-06-03
Director/Board Member 50 2018-06-03
Director/Board Member 66 2020-12-15
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Free

Director

13,698 0.0515%
6/3/26 Free

Director

13,698 0.0515%
6/3/26 Free

Director

13,698 0.0515%
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%-4.24%+22.45% - 426M
-0.42%-1.84%-18.51%+7.61% 187B
+1.15%+3.88%+1.37%+17.82% 120B
-1.86%+2.27%+13.15%+85.74% 63.15B
-3.40%-6.29%+12.38%+45.24% 52.36B
-1.54%-1.79%-3.98%-30.82% 50.32B
-2.02%-3.47%+9.18%-16.21% 33.17B
0.00%+4.45% - - 32.1B
-0.81%-0.33%+35.59%-15.82% 23.93B
-1.98%-8.57%-12.46%+9.05% 22.7B
Average -1.18%-1.41%+6.57%+12.82% 58.61B
Weighted average by Cap. -1.32%-0.77%-2.07%+16.43%

Financials

2026 *2027 *
Net sales 76.71M 65.97M 62.05M 56.64M 106M 7.26B 106M 736M 284M 3.72B 288M 282M 11.83B 108M 92.97M 87.44M 79.82M 149M 10.22B 150M 1.04B 401M 5.24B 406M 397M 16.68B
Net income -40.36M -34.71M -32.65M -29.8M -55.74M -3.82B -55.92M -387M -150M -1.95B -152M -148M -6.23B -40.07M -34.46M -32.41M -29.58M -55.33M -3.79B -55.51M -384M -149M -1.94B -150M -147M -6.18B
Net Debt - -
Logo Carlsmed, Inc.
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
Employees
127
Date Price Change Volume
26-09-04 US$15.60 +0.52% 46,726
26-09-03 US$15.52 -5.02% 158,805
26-09-02 US$16.34 -0.18% 116,021
26-09-01 US$16.37 +0.49% 87,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.60USD
Average target price
19.20USD
Spread / Average Target
+23.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CARL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!